Lexaria Bioscience reports additional findings from DIAB-A22-1 study

Lexaria Bioscience reports upon additional findings from its diabetes animal study DIAB-A22-1, and also provide updates on two other applied R&D programs. As announced on March 2, 2023, Lexaria completed initial testing using DehydraTECH-CBD in its diabetes animal model study that produced three positive outcomes including weight loss in obese diabetic-conditioned animals, together with improved triglyceride and cholesterol levels. Following this, Lexaria undertook a further round of analysis to explore additional study outcomes, including the use of an alternate blood glucose assay detection system with higher detection sensitivity than was used in the initial testing round. Using the Antech hexokinase blood chemistry test panel methodology, Lexaria discovered that blood glucose levels were statistically significantly lowered by 19.9 +/- 7% in the obese diabetic-conditioned animals treated with the DehydraTECH-CBD 30 mg/Kg dose compared to the obese vehicle control animals. This appears to be a new discovery of a property not generally known to be associated with generic CBD treatment. Kidney function was also evaluated compared to the vehicle control animals by examination of the levels of blood urea nitrogen, creatinine, and assessment of the BUN/creatinine ratio. BUN levels were reduced by 27.9% +/- 5% in the obese animals receiving DehydraTECH-CBD. Creatinine levels were also improved with a 16.8% +/-7% increase in the obese animals receiving DehydraTECH-CBD, although this improvement was not statistically significant. Astonishingly, the calculated BUN/creatinine ratio in the obese animals being treated with DehydraTECH-CBD returned to a healthy range nearly equal to that of the lean animals, with a 55.1% +/-16% reduction. This may reflect an effect of DehydraTECH-CBD to correct abnormal kidney function in this animal model as another prospective benefit in treating pathological conditions commonly associated with diabetes. DehydraTECH-CBD’s ability to reduce blood sugar levels in animals is extremely encouraging and certainly warrants additional investigation. According to the Center for Disease Control, managing your blood sugar levels is important to avoid diabetes-related conditions such as vision loss, heart disease, and kidney disease. Generic CBD has not, in general, been found to be effective in controlling blood sugars and the Company has not yet discovered whether DehydraTECH-CBD might be effective in blood-sugar control in humans.